Searchable abstracts of presentations at key conferences in endocrinology

ea0073aep467 | Pituitary and Neuroendocrinology | ECE2021

The GLP-1 receptor agonist dulaglutide reduces fluid intake in primary polydipsia: A randomised controlled trial

Winzeler Bettina , Sailer Clara , David Coynel , Zanchi Davide , Vogt Deborah , Urwyler Sandrine , Refardt Julie , Christ-Crain Mirjam

BackgroundPrimary polydipsia, characterized by excessive fluid intake, carries the risk of water intoxication and hyponatremia, but treatment options are scarce. Glucagon-like peptide-1 (GLP-1) reduces appetite and food intake. In experimental models, they also play a role in thirst and drinking behavior. The aim of this trial was to investigate whether GLP-1 receptor agonists reduce fluid intake in patients with primary polydipsia.<p class="abstext"...

ea0081p76 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

Glucagon-like peptide-1 analogues: a new way to quit smoking? SKIP – a randomised controlled study

Lengsfeld Sophia , Burkard Thilo , Meienberg Andrea , Jeanloz Nica , Vukajlovic Tanja , Bologna Katja , Steinmetz Michelle , Sailer Clara , Coynel David , Vogt Deborah R , Hemkens Lars G. , Speich Benjamin , Kuhne Jill , Baur Fabienne , Lutz Linda , Bathelt Cemile , Zanchi Davide , Christ-Crain Mirjam , Winzeler Bettina

Background: Cigarette smoking is the leading preventable cause of premature death. Smoking cessation is one of the central goals in medicine, but despite dedicated programs, quit rates remain low due to barriers such as nicotine withdrawal syndrome or post-cessation weight gain. Glucagon-like peptide-1 (GLP-1) analogues reduce energy intake and body weight and seem to modulate addictive behavior. These GLP-1 properties are of major interest in the context of smoking cessation....